Groups urge Fed Circ to rehear Biogen patent case
18-01-2022
Biogen sues Teva over MS generic
18-03-2021
Mylan launches Tecfidera generic amid Biogen battle
20-08-2020
Formatoriginal / Shutterstock.com
The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
fumarate, dimethyl, Federal, Circuit, Mylan, OMalley, Tecfidera, Biogens, dissent, Reyna, generic, description, court, claims, patent, infringement
